iifl-logo

Alembic Pharmaceuticals Ltd Historical Data

875.45
(-0.58%)
Apr 25, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Alembic Pharmaceuticals Ltd Historical Data

26/03/2025calendar-icon
26/04/2025calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

26-Mar-2025

931.9

936.05901.5904.913,79310,68,22,827.9532,864

27-Mar-2025

902.85

941.3894.15931.2520,19213,88,64,952.4568,048

28-Mar-2025

937.25

937.25896.05929.7523,89517,21,95,374.658,393

01-Apr-2025

921.95

921.95891.3896.8512,2829,20,09,064.431,399

02-Apr-2025

904.8

906.3877.7588511,8058,26,54,330.834,561

03-Apr-2025

898.25

922.85873.15887.1525,73122,97,33,485.268,753

04-Apr-2025

894.95

903863.55881.2512,91416,36,46,166.11,03,290

07-Apr-2025

775.5

854.05774.4844.9514,5387,13,33,214.228,107

08-Apr-2025

859.05

861836.6848.9510,7257,52,02,164.6527,947

09-Apr-2025

856.35

856.35830840.312,0186,18,79,974.7522,111

11-Apr-2025

848

865.15836.05846.428,59714,83,04,262.584,160

15-Apr-2025

853.95

860.45838846.4512,87710,59,59,670.5550,117

16-Apr-2025

847

865.5840.5851.9517,92413,83,21,851.1563,093

17-Apr-2025

846.6

860.95842.75849.921,59125,53,39,270.11,77,381

21-Apr-2025

856

856842.2849.6516,35719,00,82,580.851,48,204

22-Apr-2025

855.8

861.4844.85855.820,19228,21,55,107.32,32,850

23-Apr-2025

859.8

908.2852.65883.839,24245,59,64,043.151,51,891

24-Apr-2025

884.9

918.65875.65880.5527,68927,89,71,087.784,252

Alembic Pharma: Related NEWS

Alembic Pharma Gets USFDA Nod for Carbamazepine 200 mg
17 Apr 2025|02:49 PM

The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.

Read More
Alembic Pharma Secures USFDA Approval for Pantoprazole Injection
1 Apr 2025|01:58 PM

This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment 

Read More
Alembic Pharma’s Vadodara Plant Gets VAI Status from US FDA
15 Feb 2025|12:00 PM

Following an inspection carried out from Nov 14-22 2024, the facility was cited as being ‘VAI’ (Voluntary Action Indicated).

Read More
Alembic Pharma reports 23% decline in Q3 net profit
4 Feb 2025|08:49 AM

EBITDA margin came in at 15.4% in the quarter under review as compared to 16.30% in the previous corresponding period.

Read More
Alembic Pharma gets USFDA approval for generic heart failure medication
13 Nov 2024|09:20 AM

The authorised ANDA is a therapeutic equivalent of the reference-listed drug (RLD), Corlanor tablets, in the same 5 mg and 7.5 mg dosages.

Read More
Alembic Pharma gets USFDA approval hypertension drug
11 Nov 2024|12:54 PM

These medications are also used to treat chronic stable angina and angina induced by coronary artery spasm.

Read More
Alembic Pharma Gets USFDA Approval for Diltiazem ER Capsules
21 Oct 2024|12:26 PM

Alembic Pharmaceuticals continues to grow its footprint in the US, with this approval contributing to its robust portfolio of generic medications.

Read More
Alembic Pharma's Gujarat plant clears USFDA inspection
9 Oct 2024|03:09 PM

The business stated that the authorised ANDA is therapeutically similar to the reference-listed drug product (RLD) Lastacaft Solution.

Read More
Alembic Pharma Shares Jump on USFDA Approval for Lamotrigine Tablets
4 Oct 2024|10:39 AM

The approved Lamotrigine Extended-Release tablets are therapeutic equivalents of GlaxoSmithKline's Lamictal XR, with strengths of 200 mg, 250 mg, and 300 mg.

Read More
Alembic Pharmaceuticals Gets US FDA Approval for Dabigatran Etexilate Capsules
13 Aug 2024|12:48 PM

Alembic Pharmaceuticals has got the final approval from USFDA for Dabigatran Etexilate Capsules, 110 mg.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.